Statistics from Altmetric.com
There is an urgent need for new therapeutic options for hepatocellular carcinoma (HCC), which is currently the third cause of cancer-related death worldwide.1 HCC develops most frequently in the setting of cirrhosis. This premalignant condition occurs as a consequence of chronic liver disease, mainly as a result of hepatitis B and C viral infection, alcohol abuse and obesity. The poor efficacy of many antiproliferative agents against HCC is due in part to the inefficient drug delivery and metabolism in cirrhotic livers, leading to unbearable drug toxicity. Novel therapies for HCC could be developed after the identification of oncogenic addiction loops or primary ‘gatekeeper’ and ‘driver’ mutations that would allow for HCC initiation and progression, respectively.
To this end, previous large-scale studies in HCC have focused on searching for DNA mutations and transcriptome alterations. This allowed the classification of HCCs with DNA mutations that affect different pathways, that is, β-catenin signalling, P53/cell cycle control, chromatin remodelling and/or PI3K/Ras cascade.2 However, no driver DNA mutations have been identified for at least 20% HCCs,2 suggesting that other mutator or driver events could occur. To search for such alternative events, new genome-wide studies should be performed to analyse whether the transcriptome modification caused by changes in alternative splicing, alternative polyadenylation or RNA editing could have an impact on hepatocarcinogenesis.
RNA editing has now entered the limelight in HCC thanks to the study of Chan and colleagues,3 which positions RNA editing as a generator of tumour-specific transcriptome …
Contributors Both authors contributed equally to revise the original paper by Chang et al, to write the commentary and approved the final version of the manuscript.
Funding PF is supported by grants from Ministerio de Economia SAF2012-40003, FEDER funding, funds from the ‘UTE project CIMA’ and by the project RNAREG (CSD2009-00080), funded by the Ministry of Science and Innovation under the programme CONSOLIDER INGENIO 2010. SC is funded by the Institut National de la Santé et de la Recherche Médicale (INSERM), by the Agence Nationale de la Recherche (ANR) for ‘Wnt-Metaboliv’ 2010-ANR-Blanc project and by the Ligue Nationale contre le Cancer (labellisation programme 2011–2013).
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.